Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors

Open Access

1 March 2004

journal article
Published by Oxford University Press (OUP) in Clinical Infectious Diseases

Vol. 38 (Supplement) , S90-S97
https://doi.org/10.1086/381444

Abstract

Since their introduction, hepatotoxicity has been associated with the use of human immunodeficiency virus (HIV)-1 protease inhibitors (PIs). However,

Keywords

This publication has 29 references indexed in Scilit:

Antiretroviral drug toxicity – a challenge for the hepatologist?
Journal of Hepatology, 2002
Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: Role of hepatitis C and B infections
Hepatology, 2002
Risk Factors for Severe Hepatic Injury After Introduction of Highly Active Antiretroviral Therapy
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
Risk Factors for Hepatotoxicity in Patients Treated With Highly Active Antiretroviral Therapy
JAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
Reactivation of Hepatitis B Virus Replication Accompanied by Acute Hepatitis in Patients Receiving Highly Active Antiretroviral Therapy
Clinical Infectious Diseases, 2001
Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients
Antimicrobial Agents and Chemotherapy, 2000
Risk Factors for Hepatotoxicity in HIV-1--Infected Patients Receiving Ritonavir and Saquinavir with or without Stavudine
Clinical Infectious Diseases, 2000
Single and multiple dose pharmacokinetics of nelfinavir and CYP2C19 activity in human immunodeficiency virus‐infected patients with chronic liver disease
British Journal of Clinical Pharmacology, 2000
Severe hepatic cytolysis: incidence and risk factors in patients treated by antiretroviral combinations Aquitaine Cohort, France, 1996-1998
AIDS, 1999
Ritonavir
Clinical Pharmacokinetics, 1998